#AXON #GNCA #PTCT #ZYNE #ZGNX the biotech movers week of September 25 -29, 2017.

Kristin Alonzo

29-Oct-2017 09:54 AM



Last week Biotech performers

  1.  AXON -72.47% ~  failed Phase 3 MINDSET
  2. GNCA +72.40%  ~ Ceased GEN 003 and shifted towards Immunocology.
  3. ZYNE +34.19%  ~  ZYN002 gel meets primary endpoint in Phase 2 Fragile X syndrome trial.
  4. PTCT +8.05% ~  - FDA meeting for Translana seen as negative by majority of Analysts & Social media's                                 biotech gurus.  Stock price gone deep red -23% to positive territory.
  5. ZGNX +172.23%  (*Meets endpoint ZX008 of Phase 3 trial for Dravet syndome*)


Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.